- Pfizer Plans to Cut Up to 2,400 in Sales Staff
- Layoffs Picking Up Speed—Is Your Firm On the List?
- Worst Is Over for Banks—Not Economy: Pimco's Gross
- Obama: Economy Will Worsen Even With Stimulus
- What's In the Stimulus Plan
- GE Capital to Slash Up to 11,000 Jobs to Cut Costs
- US Weighs New Plan to Buy Banks' Bad Assets: Bair
- Barclays, UK Banks Crash on Short-Selling, Jitters
- Where Has the TARP Bailout Money Gone?
- Your First Move For Tuesday January 20th
- Web Extra: Sign Of Bottom For Autos?
- Big Earnings on Deck
- Ratigan Favorite: The Bailout Video Game
- Pops & Drops: McDonald's, Kimberly-Clark...
- Investing In Uncle Sam’s Shadow
- Is a “Bad Bank” The Answer?
- Stocks Rise In Face Of Bank Bailouts
- Market Orders Are for Suckers
Text Size 
Amgen, the world's largest biotechnology company, said Friday the U.S. Food and Drug Administration has accepted its application to sell experimental drug denosumab as a treatment for osteoporosis in post-menopausal women.
The application also covers treatment and prevention of bone loss in patients undergoing hormone ablation for either prostate or breast cancer.
Denosumab is viewed as the next key growth engine at Amgen [AMGN
Loading...
()
] , which has seen sales of its flagship anemia drugs slide after the emergence of data two years ago showing the drugs raised the risk of death for some cancer patients.
For Investors:
- For After-Hours Amgen Quotes, Click Here
- For After-Hours Quotes on the Dow 30 Components, Click Here
- Vertex's $75,000 Question
The Thousand Oaks, California-based company said in September that a large trial of denosumab in post-menopausal women suffering from osteoporosis showed it reduced the risk of some spine fractures by about 68 percent.
The company is also developing the drug as a treatment for cancer patients.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes